{"entity":{"id":"nct07743112","kind":"trial","name":"A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia","aka":[],"tldr":"A phase 2 trial of Azacitidine and Venetoclax in acute myeloid leukaemia, run by Maxinovel Pty., Ltd., now recruiting.","summary":"A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia is a phase 2 interventional study registered as NCT07743112 by Maxinovel Pty., Ltd., with 43 participants planned, started 2025-09-05 and due to reach its primary completion in 2027-09-01. Interventions recorded: MAX-40279, Azacitidine and Venetoclax.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07743112","url":"https://clinicaltrials.gov/study/NCT07743112"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":["azacitidine","venetoclax"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07743112","phase":"2","setting":"A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia","sponsor":"Maxinovel Pty., Ltd.","enrolled":43,"outcomes":[]},"route":"/trials/nct07743112/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"drug":[{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}]}}